# LaMB (NCT00949455)

> A Double Blind Randomised Study of Lapatinib and Placebo in Metastatic TCC of the Urothelium

No report yet. It can be ordered.

- Drugs tested: lapatinib
- Indication: HER1 and/or HER2 overexpressing advanced bladder cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT00949455
- Phase: PHASE2, PHASE3
- Status: UNKNOWN
- Sponsor: Queen Mary University of London
- Conditions: Bladder Cancer
- Interventions: lapatinib ditosylate; Placebo
- Enrollment: 204
- Primary outcome: Progression free survival

## Indexed commentary on LaMB so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 3
- Podcasts: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=lamb-nct00949455